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of 128 scenarios was selected from 729 possible scenarios (3
power 6) in order to test second-order interactions. Interviews
with 21 healthcare professionals (nurses and nursing auxiliaries)
ascertained the duration of assistance required for 18 of the 128
scenarios, selected at random. The economic perspective was
that of society. The link between time spent, costs, and factor
scores was derived from linear and non-linear models. These
functions were applied to the 16,945 subjects in order to esti-
mate the assistance time required. Comparisons between blind,
low vision and control subjects were performed using an
ANOVA with adjustments for age, number of people in the
household, and number of handicaps. RESULTS: Average care-
hours per annum were 682.7 for blind people, 261.4 hours for
low vision subjects, and 147.5 for controls. The annual care
budget was 6750€ for blind subjects, and 1463€ for subjects with
low vision. The total mean yearly nationwide care cost to fami-
lies for visual impairment was estimated at 2025.9€m. CON-
CLUSIONS: Screening and treatment programs aimed at
preserving vision should beneﬁt society and would help to reduce
expenditures on assistance time due to visual impairment.
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OBJECTIVES: To estimate the non-medical costs related to
visual impairment in four European countries. METHODS:
Counts of visually impaired people, deﬁned according to local
rules, were extracted from National Registers, and for France
from two recent nation-wide surveys realized by INSEE. Esti-
mated numbers of non-registered persons were based on the lit-
erature and expert opinion. Estimation of non-medical cost
included stay in institution, medical devices, home adaptations,
burden on carer, paid home help, loss of income and social
allowances related to visual impairment. Unit costs were
obtained from National databases, local manufacturers and the
Web. Also, in France, interviews were conducted on 21 health-
care professionals to estimate the duration of assistance required
by visually impaired people. These durations were used to eval-
uate the cost of paid home help in each of the four countries.
RESULTS: Visually impaired subjects in France, Germany, Italy
and the UK numbered, respectively, 1.27, 0.73, 1.03 and 1.11
million, including 55,9%, 10%, 80%, and 64% non-registered
persons. The institutionalization rate of visually impaired
persons were 7.8%, 9.6%, 10.9% and 10.0%, respectively. Total
annual costs for visually impaired people were estimated at
10,749€m, 9338€m, 12,069€m, and 15,180€m in France,
Germany, Italy and the UK, respectively. The main costs attrib-
utable to visual impairment were “loss of income” (22.6% to
42.5%), “burden on carer” (23.5% to 38.6%), “paid assistance”
(12.4% to 27.8%) and “social allowances” (4.8% to 8.8%).
CONCLUSIONS: The total non-medical costs attributable to
visual impairment are considerable, amounting to 8.1%, 4.7%,
12.4%, and 14.9% of the National Health expenditure of
France, Germany, Italy and the UK, respectively. However, they
were under-estimated because many blind people were not reg-
istered. Also, the total costs did not include allowances that
should have been paid to non-registered persons.
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OBJECTIVES: To compare the cost of disposable items used
during cataract surgery with and without Custom Pak ® in two
French public centres. METHODS: Custom Pak ® is a cus-
tomised package that provides all the necessary disposable
devices speciﬁed by a surgeon for cataract surgery in one sterile
bag. An exploratory time and motion analysis of cataract surg-
eries at two well-known French public centres was carried out
to compare operations performed with the customized versus
regular set ups. The time and category of employees involved
during the cataract surgery was recorded from the start to the
ﬁnish of the operation. Moreover, the time costs of profession-
als was calculated from available information. The potential for
increasing turnover to the hospitals was also estimated.
RESULTS: The main time savings beneﬁt with the Custom Pak®
was observed during the preparation phase of the cataract sur-
gical intervention. The mean time of surgical preparation was
decreased by 10.45 minutes with a total time deceased of 16.15
minutes for the individual surgeon. The savings associated with
this gain in time was estimated to be 17.63€ as compared with
an incremental Custom Pak ® cost of 11.30€. During one oper-
ating session of 4 hours, the Custom Pak ® allowed the hospi-
tals to perform 1.02 more cataract operations (n = 4.36 cataract
operations without Custom Pak® and n = 5.38 cataract opera-
tions with Custom Pak®) and to increase the overall hospital
turn-over by 1863€, that is, the amount paid for this extra
cataract surgery to the public hospital at an additional costs of
61€ for Custom Pak® devices. CONCLUSIONS: Overall, the
Custom Pak ® increases the productivity and potential for
turnover associated with performing cataract surgery. This
increased turnover easily exceeds the extra cost of the customized
package.
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OBJECTIVES: To analyze the prevalence of local antiglaucoma
medicines in drug-store of Russia and to make the pharmaeco-
nomical research on the base of large statistical selection.
METHODS: In 2003, the total cost of antiglaucoma medicines
sales in drug-stores of Russia was about 10.86m USD. The beta-
blockers took the ﬁrst place ($7.0m or 64.4%. The pilocarpine
analogue medicines took the second place. Their joint sales
volume was $1.8m or 16.7%. Two combined medicines Fotil
and Fotil forte (Santen) were at the third place $1.2m (10.7%).
Latanoprost (Xalatan, Pharmacia-Pﬁzer) and Brinzolamide
(Azopt, Alcon) began to be saled more active. The sales of the
ﬁrst, in 2003, were 3.8%. Azopt began to be saled only in 2002
and its results are $147,878.15 or 1.35% and in 2003—
$289,265 (2.7%) The other CAI Trusopt (MSD) was pharma-
coeconomical in 2002 on $217,473.86 (1.99%) and in 2003
$184,713 (1.7%). The portion of all other medicines in 2002
was less than 0.5%. The average price of beta-blocers is 0.7-
$2.1, CAIs about $22; prostaglandins and their combination
(Xalacom, Pﬁzer—sales started only in the end of 2002 year in
Russian market) $25.6 and $26.9; combined form (timolol +
pilocarpine) $5; pilocarpine $0.83 round the clock and the
course of treatment during a one year is $11.92 (pilocarpine)
$380.32 (Trusopt). RESULTS: The timolol maleate, pilocarpine
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and their combination are medicines of choice for treatment of
glaucoma in Russia. CONCLUSIONS: More attention is being
payed to prostaglandins and CAIs. The information of ophthal-
mologist and their patients about the cost of therapy is a very
important component for pharmacoeconomical decisions
together with medical effectiveness of treatment. But it is rather





RESPONSIVENESS OF SELF-REPORTED VISUAL
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OBJECTIVES: Evaluate association of National Eye Institute
Visual Functioning Questionnaire-25 (VFQ-25) score changes
with systemic comorbidities and visual acuity (VA) changes in
neovascular AMD patients in a phase I/II randomized controlled
trial of LucentisTM (ranibizumab; rhuFab V2). METHODS: At
baseline and three months, 57 patients completed the VFQ-25
(self-reported visual function) and VA was measured. The pres-
ence of seven comorbidities was recorded at baseline. VA score
(number of lines read) was converted to a weighted log of the
minimum angle of resolution (0.25 worse eye logMAR + 0.75
better eye logMAR). To estimate the relative association of
changes in VA and comorbidities with changes in VFQ-25 scores,
separate regression models of three-month changes in each sub-
scale score on the logMAR scores were developed for each
comorbidity. RESULTS: Mean number of comorbidities was 3,
including: 25 (44%) hypertension, 24 (42%) arthritis, 14 (25%)
hearing loss, 12 (21%) diabetes, 12 (21%) psychiatric disease,
12 (21%) back pain, 11 (19%) cancer. Due to small sample size,
only VA estimates in the regression were signiﬁcant after con-
trolling, individually, for the comorbidities. For all models, a
one-line (0.1 logMAR) worsening in VA was signiﬁcantly asso-
ciated with decreased subscale scores, particularly those related
to central vision (Near Activities, Distance Activities). VA alone
explained 11% of the variation in the VFQ-25 change between
baseline and 3 months in the Near Activities subscale. Inclusion
of an individual comorbidity improved the explanatory power
of the models slightly (r2): to 12% for hypertension, hearing loss,
diabetes, psychiatric disease, cancer, and back pain, 13% for
arthritis subjects, and 14% when summing all comorbidites a
patient had. CONCLUSIONS: Some selected VFQ-25 subscale
scores were decreased with the presence of visual impairment
and comorbidities. Systemic diseases should be included in VFQ-
25 assessments to control for differences between patients and
samples.
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OBJECTIVES: Assess the impact of atopic dermatitis (AD) on
parent’s quality of life (QoL) and use of health direct resources
in patients between 2 and 12 years old. METHODS: An obser-
vational burden-disease study of nine months of follow-up in
which AD patients 2 to 12 years old were included according to
Haniﬁn&Rajka diagnostic criteria. Four visits were conducted
per protocol (baseline, 3, 6, 9 months). Disease severity was
assessed by Investigator’s Global Assessment(IGA). Parents’ QoL
was assessed by Parents Index of Quality of Life Atopic Der-
matitis (PiQoL-AD) and by Visual Analogue Scale(VAS) of the
EQ-5D questionnaire. Use of direct resources in the last three
months were assessed retrospectively by medical ﬁles data or
direct interviews to patients’ parents. RESULTS: Results are
referred to baseline visit. A total of 240 children with AD were
included in the analysis, with mean age (SD) 5.3 (2.7), 52% were
boys. The most frequent careers were mothers (87.8%), 36.24
(4.9) years older (mean(SD)). 19.18% of patients had clear or
almost clear AD (IGA < 2), 31.25% had mild disease (IGA = 2),
37.91% had moderate disease (IGA = 3) and 11.68% had severe
or very severe disease (IGA = 4 or IGA = 5). Disease severity had
a signiﬁcant impact on parent’s QoL: mean scores of PIQoL-AD
questionnaire increased 4.9 points and VAS score decrease 16.28
points (p < 0.5), indicating a worsening health state. In the last
3 months, 79.69% of patients required medical assistance,
mainly from paediatricians or dermatologists; 81.84% pharma-
cological treatment and 24.11% laboratory tests, 17.61%
unscheduled visits and 12.73% went to the Emergency Depart-
ment. Use of direct resources increased with severity (p < 0.5).
CONCLUSIONS: Parents’ QoL tends to reduce progressively
from mild AD states while resource utilization increases pro-
gressively. Proper management of AD may help maintain patients
in less severe disease states, reducing the negative impact on
quality of life and on resource utilization.
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OBJECTIVES: The Dermatology Life Quality Index (DLQI) is a
widely-used HRQL measure. The instrument is intended for use
by patients with any skin disease. The aim of this study was to
assess the scaling properties of the DLQI and whether it is free
from differential item functioning (DIF). METHODS: DLQI
data collected in atopic dermatitis (AD) and psoriasis studies in
the UK were subjected to Rasch (one-parameter logistic item
response theory) analysis. Fit to the Rasch model was examined
via Chi2 statistics and assessments of DIF related to gender, age
and type of skin disease were made. RESULTS: Sample: Psoria-
sis study: n = 148 (49.7% male; mean age 45.1 +/- 14.9; mean
illness duration 20.9 +/- 13.5; mean DLQI score 8.7 +/- 6.7);
AD study: n = 286 (29.4% male; mean age 44.9 +/- 16.4; mean
illness duration 29.0 +/- 16.7; mean DLQI score 7.0 (+/-5.1).
The DLQI showed signiﬁcant misﬁt to the Rasch model in pso-
riasis and AD—indicating that the instrument is not unidimen-
sional. Several DLQI items exhibited DIF by age and gender.
Four of the ten items in the measure exhibited DIF by disease.
CONCLUSIONS: The DLQI was found to misﬁt the Rasch
model in both patient samples, indicating that it is unsafe to use
the total score on the measure. Its validity is further compro-
mised by DIF associated with age and gender which indicates
that items work differently with different subgroups of patients.
For example, the item “How much has your skin inﬂuenced the
